Chiara Nardocci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chiara Nardocci has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Judit Simon
Semmelweis University, Budapest, Hungary
4 shared publications - Pál Maurovich-Horvat
MTA-SE Cardiovascular Imaging Research Group, Department of Radiology, Medical Imaging Centre, Semmelweis University, Hungary
4 shared publications - Veronika Müller
Department of Pulmonology, Semmelweis University , Budapest
4 shared publications - Emese Zsarnóczay
Department of Radiology, Medical Imaging Centre, Semmelweis University , 2 Koranyi Sandor u, Budapest 1083
3 shared publications - Norbert Nagy
Medical Imaging Centre, Semmelweis University, Budapest, Hungary
3 shared publications - Anna Sára Kardos
Medical Imaging Centre, Semmelweis University , Budapest , Hungary
2 shared publications
Latest Publications
- Open Access
- 26 June 2024
- Published by Akademiai Kiado Zrt. in Imaging
- Vol. 16 (1) , 1-21
Artificial intelligence-based quantification of COVID-19 pneumonia burden using chest CT
During the coronavirus disease 2019 (COVID-19) pandemic, artificial intelligence (AI) based software on chest computed tomography (CT) imaging has proven to have a valuable role in accelerating diagnosis and screening. The proposed AI-based tools proved to be rapid and reproducible techniques to guide patient management and treatment protocols. Although no specific guidelines exist, CT-imaging and clinical features are used for patient staging. To shed light on the role of AI techniques that have been developed in fighting COVID-19, in this review, studies investigating the usage of commonly used AI models on chest CT imaging for disease quantification and prognostication are collected.
- 26 June 2024
- Published by Akademiai Kiado Zrt. in Imaging
- Vol. 16 (1) , 1-21
Open AccessArtificial intelligence-based quantification of COVID-19 pneumonia burden using chest CT
During the coronavirus disease 2019 (COVID-19) pandemic, artificial intelligence (AI) based software on chest computed tomography (CT) imaging has proven to have a valuable role in accelerating diagnosis and screening. The proposed AI-based tools proved to be rapid and reproducible techniques to guide patient management and treatment protocols. Although no specific guidelines exist, CT-imaging and clinical features are used for patient staging. To shed light on the role of AI techniques that have been developed in fighting COVID-19, in this review, studies investigating the usage of commonly used AI models on chest CT imaging for disease quantification and prognostication are collected.
- Open Access
- 2 May 2022
- Published by Oxford University Press (OUP) in BJR|Open
- Vol. 4 (1) , 20220016
Radiomorphological signs and clinical severity of SARS-CoV-2 lineage B.1.1.7
Objective: We aimed to assess the differences in the severity and chest-CT radiomorphological signs of SARS-CoV-2 B.1.1.7 and non-B.1.1.7 variants. Methods: We collected clinical data of consecutive patients with laboratory-confirmed COVID-19 and chest-CT imaging who were admitted to the Emergency Department between September 1– November 13, 2020 (non-B.1.1.7 cases) and March 1–March 18, 2021 (B.1.1.7 cases). We also examined the differences in the severity and radiomorphological features associated with COVID-19 pneumonia. Total pneumonia burden (%), mean attenuation of ground-glass opacities and consolidation were quantified using deep-learning research software. Results: The final population comprised 500 B.1.1.7 and 500 non-B.1.1.7 cases. Patients with B.1.1.7 infection were younger (58.5 ± 15.6 vs 64.8 ± 17.3; p < .001) and had less comorbidities. Total pneumonia burden was higher in the B.1.1.7 patient group (16.1% [interquartile range (IQR):6.0–34.2%] vs 6.6% [IQR:1.2–18.3%]; p < .001). In the age-specific analysis, in patients <60 years B.1.1.7 pneumonia had increased consolidation burden (0.1% [IQR:0.0–0.7%] vs 0.1% [IQR:0.0–0.2%]; p < .001), and severe COVID-19 was more prevalent (11.5% vs 4.9%; p = .032). Mortality rate was similar in all age groups. Conclusion: Despite B.1.1.7 patients were younger and had fewer comorbidities, they experienced more severe disease than non-B.1.1.7 patients, however, the risk of death was the same between the two groups. Advances in knowledge: Our study provides data on deep-learning based quantitative lung lesion burden and clinical outcomes of patients infected by B.1.1.7 VOC. Our findings might serve as a model for later investigations, as new variants are emerging across the globe.
- 2 May 2022
- Published by Oxford University Press (OUP) in BJR|Open
- Vol. 4 (1) , 20220016
Open AccessRadiomorphological signs and clinical severity of SARS-CoV-2 lineage B.1.1.7
Objective: We aimed to assess the differences in the severity and chest-CT radiomorphological signs of SARS-CoV-2 B.1.1.7 and non-B.1.1.7 variants. Methods: We collected clinical data of consecutive patients with laboratory-confirmed COVID-19 and chest-CT imaging who were admitted to the Emergency Department between September 1– November 13, 2020 (non-B.1.1.7 cases) and March 1–March 18, 2021 (B.1.1.7 cases). We also examined the differences in the severity and radiomorphological features associated with COVID-19 pneumonia. Total pneumonia burden (%), mean attenuation of ground-glass opacities and consolidation were quantified using deep-learning research software. Results: The final population comprised 500 B.1.1.7 and 500 non-B.1.1.7 cases. Patients with B.1.1.7 infection were younger (58.5 ± 15.6 vs 64.8 ± 17.3; p < .001) and had less comorbidities. Total pneumonia burden was higher in the B.1.1.7 patient group (16.1% [interquartile range (IQR):6.0–34.2%] vs 6.6% [IQR:1.2–18.3%]; p < .001). In the age-specific analysis, in patients <60 years B.1.1.7 pneumonia had increased consolidation burden (0.1% [IQR:0.0–0.7%] vs 0.1% [IQR:0.0–0.2%]; p < .001), and severe COVID-19 was more prevalent (11.5% vs 4.9%; p = .032). Mortality rate was similar in all age groups. Conclusion: Despite B.1.1.7 patients were younger and had fewer comorbidities, they experienced more severe disease than non-B.1.1.7 patients, however, the risk of death was the same between the two groups. Advances in knowledge: Our study provides data on deep-learning based quantitative lung lesion burden and clinical outcomes of patients infected by B.1.1.7 VOC. Our findings might serve as a model for later investigations, as new variants are emerging across the globe.
- Open Access
- 30 November 2021
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 95 (1129) , 20210759
The diagnostic performance of deep-learning-based CT severity score to identify COVID-19 pneumonia
Objective: To determine the diagnostic accuracy of a deep-learning (DL)-based algorithm using chest computed tomography (CT) scans for the rapid diagnosis of coronavirus disease 2019 (COVID-19), as compared to the reference standard reverse-transcription polymerase chain reaction (RT-PCR) test. Methods: In this retrospective analysis, data of COVID-19 suspected patients who underwent RT-PCR and chest CT examination for the diagnosis of COVID-19 were assessed. By quantifying the affected area of the lung parenchyma, severity score was evaluated for each lobe of the lung with the DL-based algorithm. The diagnosis was based on the total lung severity score ranging from 0 to 25. The data were randomly split into a 40% training set and a 60% test set. Optimal cut-off value was determined using Youden-index method on the training cohort. Results: A total of 1259 patients were enrolled in this study. The prevalence of RT-PCR positivity in the overall investigated period was 51.5%. As compared to RT-PCR, sensitivity, specificity, positive predictive value, negative predictive value and accuracy on the test cohort were 39.0%, 80.2%, 68.0%, 55.0% and 58.9%, respectively. Regarding the whole data set, when adding those with positive RT-PCR test at any time during hospital stay or “COVID-19 without virus detection”, as final diagnosis to the true positive cases, specificity increased from 80.3% to 88.1% and the positive predictive value increased from 68.4% to 81.7%. Conclusion: DL-based CT severity score was found to have a good specificity and positive predictive value, as compared to RT-PCR. This standardized scoring system can aid rapid diagnosis and clinical decision making. Advances in knowledge: DL-based CT severity score can detect COVID-19-related lung alterations even at early stages, when RT-PCR is not yet positive.
- 30 November 2021
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 95 (1129) , 20210759
Open AccessThe diagnostic performance of deep-learning-based CT severity score to identify COVID-19 pneumonia
Objective: To determine the diagnostic accuracy of a deep-learning (DL)-based algorithm using chest computed tomography (CT) scans for the rapid diagnosis of coronavirus disease 2019 (COVID-19), as compared to the reference standard reverse-transcription polymerase chain reaction (RT-PCR) test. Methods: In this retrospective analysis, data of COVID-19 suspected patients who underwent RT-PCR and chest CT examination for the diagnosis of COVID-19 were assessed. By quantifying the affected area of the lung parenchyma, severity score was evaluated for each lobe of the lung with the DL-based algorithm. The diagnosis was based on the total lung severity score ranging from 0 to 25. The data were randomly split into a 40% training set and a 60% test set. Optimal cut-off value was determined using Youden-index method on the training cohort. Results: A total of 1259 patients were enrolled in this study. The prevalence of RT-PCR positivity in the overall investigated period was 51.5%. As compared to RT-PCR, sensitivity, specificity, positive predictive value, negative predictive value and accuracy on the test cohort were 39.0%, 80.2%, 68.0%, 55.0% and 58.9%, respectively. Regarding the whole data set, when adding those with positive RT-PCR test at any time during hospital stay or “COVID-19 without virus detection”, as final diagnosis to the true positive cases, specificity increased from 80.3% to 88.1% and the positive predictive value increased from 68.4% to 81.7%. Conclusion: DL-based CT severity score was found to have a good specificity and positive predictive value, as compared to RT-PCR. This standardized scoring system can aid rapid diagnosis and clinical decision making. Advances in knowledge: DL-based CT severity score can detect COVID-19-related lung alterations even at early stages, when RT-PCR is not yet positive.
- Open Access
- 1 November 2021
- Published by MDPI AG in Tomography
- Vol. 7 (4) , 697-710
The Predictive Role of Artificial Intelligence-Based Chest CT Quantification in Patients with COVID-19 Pneumonia
We sought to analyze the prognostic value of laboratory and clinical data, and an artificial intelligence (AI)-based algorithm for Coronavirus disease 2019 (COVID-19) severity scoring, on CT-scans of patients hospitalized with COVID-19. Moreover, we aimed to determine personalized probabilities of clinical deterioration. Data of symptomatic patients with COVID-19 who underwent chest-CT-examination at the time of hospital admission between April and November 2020 were analyzed. COVID-19 severity score was automatically quantified for each pulmonary lobe as the percentage of affected lung parenchyma with the AI-based algorithm. Clinical deterioration was defined as a composite of admission to the intensive care unit, need for invasive mechanical ventilation, use of vasopressors or in-hospital mortality. In total 326 consecutive patients were included in the analysis (mean age 66.7 ± 15.3 years, 52.1% male) of whom 85 (26.1%) experienced clinical deterioration. In the multivariable regression analysis prior myocardial infarction (OR = 2.81, 95% CI = 1.12–7.04, p = 0.027), immunodeficiency (OR = 2.08, 95% CI = 1.02–4.25, p = 0.043), C-reactive protein (OR = 1.73, 95% CI = 1.32–2.33, p < 0.001) and AI-based COVID-19 severity score (OR = 1.08; 95% CI = 1.02–1.15, p = 0.013) appeared to be independent predictors of clinical deterioration. Personalized probability values were determined. AI-based COVID-19 severity score assessed at hospital admission can provide additional information about the prognosis of COVID-19, possibly serving as a useful tool for individualized risk-stratification.
- 1 November 2021
- Published by MDPI AG in Tomography
- Vol. 7 (4) , 697-710
Open AccessThe Predictive Role of Artificial Intelligence-Based Chest CT Quantification in Patients with COVID-19 Pneumonia
We sought to analyze the prognostic value of laboratory and clinical data, and an artificial intelligence (AI)-based algorithm for Coronavirus disease 2019 (COVID-19) severity scoring, on CT-scans of patients hospitalized with COVID-19. Moreover, we aimed to determine personalized probabilities of clinical deterioration. Data of symptomatic patients with COVID-19 who underwent chest-CT-examination at the time of hospital admission between April and November 2020 were analyzed. COVID-19 severity score was automatically quantified for each pulmonary lobe as the percentage of affected lung parenchyma with the AI-based algorithm. Clinical deterioration was defined as a composite of admission to the intensive care unit, need for invasive mechanical ventilation, use of vasopressors or in-hospital mortality. In total 326 consecutive patients were included in the analysis (mean age 66.7 ± 15.3 years, 52.1% male) of whom 85 (26.1%) experienced clinical deterioration. In the multivariable regression analysis prior myocardial infarction (OR = 2.81, 95% CI = 1.12–7.04, p = 0.027), immunodeficiency (OR = 2.08, 95% CI = 1.02–4.25, p = 0.043), C-reactive protein (OR = 1.73, 95% CI = 1.32–2.33, p < 0.001) and AI-based COVID-19 severity score (OR = 1.08; 95% CI = 1.02–1.15, p = 0.013) appeared to be independent predictors of clinical deterioration. Personalized probability values were determined. AI-based COVID-19 severity score assessed at hospital admission can provide additional information about the prognosis of COVID-19, possibly serving as a useful tool for individualized risk-stratification.
- Open Access
- 26 October 2021
- Published by Akademiai Kiado Zrt. in Imaging
- Vol. -1 (aop) , 16-27
The role of imaging in the diagnosis and management of idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease lacking a definite etiology, characterized by the nonspecific symptoms of dyspnea and dry cough. Due to its poor prognosis, imaging techniques play an essential role in diagnosing and managing IPF. High resolution computed tomography (HRCT) has been shown to be the most sensitive modality for the diagnosis of pulmonary fibrosis. It is the primary imaging modality used for the assessment and follow-up of patients with IPF. Other not commonly used imaging methods are under research, such as ultrasound, magnetic resonance imaging and positron emission tomography-computed tomography are alternative imaging techniques. This literature review aims to provide a brief overview of the imaging of IPF-related alterations.
- 26 October 2021
- Published by Akademiai Kiado Zrt. in Imaging
- Vol. -1 (aop) , 16-27
Open AccessThe role of imaging in the diagnosis and management of idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease lacking a definite etiology, characterized by the nonspecific symptoms of dyspnea and dry cough. Due to its poor prognosis, imaging techniques play an essential role in diagnosing and managing IPF. High resolution computed tomography (HRCT) has been shown to be the most sensitive modality for the diagnosis of pulmonary fibrosis. It is the primary imaging modality used for the assessment and follow-up of patients with IPF. Other not commonly used imaging methods are under research, such as ultrasound, magnetic resonance imaging and positron emission tomography-computed tomography are alternative imaging techniques. This literature review aims to provide a brief overview of the imaging of IPF-related alterations.